Please assess the completion status of the following clinical trial:

Trial Title: RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* preterm infants with a birth weight of less than 1500 g~* bilateral ROP with one of the following retinal findings in each eye: Zone I, stage 1+, 2+, 3 or 3+ disease, or Zone II, stage 3+ disease, or Aggressive posterior retinopathy of prematurity (AP-ROP)~Exclusion Criteria:~* ROP disease characteristic in either eye other than that listed above at the time of the first investigational treatment~* A history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes~* Had received any previous surgical or nonsurgical treatment for ROP (e.g., ablative laser therapy or cryotherapy, vitrectomy)~* Had been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)~* Had used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever was longer~* Had ocular structural abnormalities that were assessed by the Investigator to have had a clinically significant impact on study assessments~* Had active ocular infection within 5 days before or on the day of first investigational treatment~* Had a history of hydrocephalus requiring treatment~* Had a history of any other neurological conditions that are assessed by the Investigator to have a significant risk of severe impact on visual function~* Had any other medical conditions or clinically significant comorbidities or personal circumstances that were assessed by the Investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments (e.g., poor life expectancy, pupil not able to be adequately dilated, unable to comply with the visit schedule)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.2 mg (Type: EXPERIMENTAL): 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
- Ranibizumab 0.1 mg (Type: EXPERIMENTAL): 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
- Laser therapy (Type: ACTIVE_COMPARATOR): Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed

Based on this trial design, predict the completion outcome and termination type (if applicable).